Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

(Reuters) -Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership ...

Novavax has had an impressive run over the past six months as its shares have beaten the S&P 500 by 27.6%. The stock now ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as upfront and milestone payments from vaccine supply and licensing deals helped offset pressure ​from sagging demand, ...

Add Yahoo as a preferred source to see more of our stories on Google. Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other ...

Novavax was close to going under. In early 2023, it warned investors that it might not have enough funds to finish the year. However, the biotech has made significant changes over the past 18 months.

Although a better-than-expected Q1 earnings print has NVAX stock skyrocketing recently, there’s a high risk in chasing this biotech play.

Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a stand-alone flu vaccine, sending shares of the company down ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...

Add Yahoo as a preferred source to see more of our stories on Google. Food and Drug Administration commissioner Martin Markary speaks during an event in the Roosevelt Room at the White House, Monday, ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...